First Online: 2 May 2020
Compliance with Ethical Standards
: The writing support and development of the population pharmacokinetic model by PharmaLex were funded by the study sponsor and collaborator, Immunic AG. The authors declare that no other funding has been received for the conduct of this study.
: All authors are employees of Immunic AG and own stock of the parent company of Immunic AG.
: The protocols for SAD and MAD studies were approved by the Institutional Ethics Committee (IECs). The study was conducted in accordance with the International Conference on Harmonization Guideline for Good Clinical Practice and Declaration of Helsinki and was approved in advance by the Institutional Ethics Committee. All subjects provided written informed consents before their participation.